STOPGAP II — a national randomized clinical trial for patients with stage 4 gastric cancer
What starts at UCI Health can help shape the national conversation.
Clinical Scorecard: STOPGAP II — a national randomized clinical trial for patients with stage 4 gastric cancer
At a Glance
| Category | Detail |
|---|
| Condition | Stage 4 gastric cancer with peritoneal carcinomatosis |
| Key Mechanisms | Testing a new treatment paradigm for gastric carcinomatosis |
| Target Population | Patients with stage 4 gastric cancer |
| Care Setting | National clinical trial |
Key Highlights
- STOPGAP II is a national randomized clinical trial.
- The trial follows the successful STOPGAP I study.
- It aims to address treatment options for younger patients with advanced gastric cancer.
- The trial is accruing participants ahead of expectations.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with stage 4 gastric cancer and peritoneal carcinomatosis
The trial is designed to test new treatment approaches.
Clinical Best Practices
Related Resources & Content
